Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).

Purpose: A CTEP-sponsored phase II trial was conducted to evaluate safety and clinical activity of combination therapy with CCI-779 (temsirolimus) and bevacizumab in patients with advanced melanoma.

Experimental Design: Patients with unresectable stage III to IV melanoma were treated intravenously with temsirolimus 25 mg weekly and bevacizumab 10 mg every 2 weeks. Adverse events were recorded using CTCAE v3.

Changing the nomenclature/taxonomy for intersex: a scientific and clinical rationale.

We explain here why the standard division of many intersex types into true hermaphroditism, male pseudohermaphroditism, and female pseudohermaphroditism is scientifically specious and clinically problematic. First we provide the history of this tripartite taxonomy and note how the taxonomy predates and largely ignores the modern sciences of genetics and endocrinology. We then note the numerous ways that the existing taxonomy confuses and sometimes harms clinicians, researchers, patients, and parents.

Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.

Objective: To examine alendronates side-effect profile and effect on bone mineral density (BMD) in deflazacort-treated boys with Duchennes muscular dystrophy (DMD) and low BMD.

Design: Before-after trial.

Setting: Neuromuscular clinic at a children's hospital in Canada between 1999 and 2000.

Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures.

Patients with dialysis-dependent renal failure are at increased risk for low-trauma fractures. However, the optimal means of identifying patients at high risk for fracture is not known. We assessed the association between fracture history and two tests of bone mineral density (dual x-ray absorptiometry [DEXA] and calcaneal ultrasound) among patients with hemodialysis-dependent renal failure.